Zydus receives final approval from USFDA for Paliperidone ER Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Subscribe To Our Newsletter & Stay Updated